

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	27	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	28	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	30	JUL 30	USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:53:31 ON 02 AUG 2007

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:53:47 ON 02 AUG 2007

FILE 'EMBASE' ENTERED AT 13:53:47 ON 02 AUG 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:53:47 ON 02 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 13:53:47 ON 02 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 13:53:47 ON 02 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s CTL epitope
L1 6610 CTL EPITOPE

=> s l1 and KDR
L2 1 L1 AND KDR

=> d l2 cbib abs

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2000:240985 Document No. 132:292701 Novel methods for therapeutic
vaccination. Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus
Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand;
Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl.
WO 2000020027 A2 20000413, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT,
AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW:
AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR,
IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN:
PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261
19981005; US 1998-PV105011 19981020.

AB A method is disclosed for inducing cell-mediated immunity against cellular
antigens. More specifically, the invention provides for a method for
inducing cytotoxic T-lymphocyte immunity against weak antigens, notably
self-proteins. The method entails that antigen presenting cells are
induced to present at least one CTL epitope of the
weak antigen and at the same time presenting at least one foreign T-helper
lymphocyte epitope. In a preferred embodiment, the antigen is a cancer
specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or
FGF8b. The method can be exercised by using traditional polypeptide
vaccination, but also by using live attenuated vaccines or nucleic acid
vaccination. The invention furthermore provides immunogenic analogs of
PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs.
Also vectors and transformed cells are disclosed. The invention also
provides for a method for identification of immunogenic analogs of weak or
non-immunogenic antigens.

=> s KDR
L3 9651 KDR

=> s l3 and nonopeptide
L4 0 L3 AND NONOPEPTIDE

=> s l3 and peptide
L5 637 L3 AND PEPTIDE

=> s l5 and CTL
L6 6 L5 AND CTL

=> dup reove l6

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
'REOVE' IS NOT VALID. VALID FILE NAMES ARE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS'

You have entered a file name of duplicates to keep that is not referenced by any of the L#s specified for this DUPLICATE command. The file names of duplicates that can be kept are listed above. Please enter one of these file names.

=> dup remove l6
PROCESSING COMPLETED FOR L6
L7 2 DUP REMOVE L6 (4 DUPLICATES REMOVED)

=> d l7 1-2 cbib abs

L7 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1
2006075035. PubMed ID: 16234362. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Sun Yuansheng; Stevanovic Stefan; Song Mingxia; Schwantes Astrid; Kirkpatrick C James; Schadendorf Dirk; Cichutek Klaus. (Division of Medical Biotechnology, Paul-Ehrlich-Institute, Paul-Ehrlich-Str 51-59, D-63225 Langen, Germany.. sunyu@pei.de) . Blood, (2006 Feb 15) Vol. 107, No. 4, pp. 1476-83. Electronic Publication: 2005-10-18. Journal code: 7603509. ISSN: 0006-4971. Pub. country: United States. Language: English.

AB Antigen-specific cancer immunotherapy directed toward tumor-nourishing angiogenic blood vessels holds the promise of high efficacy, low toxicity, and ease of application. To evaluate whether the human angiogenic kinase insert domain-containing receptor (KDR) can serve as a target for cellular immunotherapy, 19 peptide sequences with HLA-A*0201 motifs were selected by computer-based algorithms. Five peptides (KDR82-90, KDR288-297, KDR766-774, KDR1093-1101, KDR1035-1044) stimulated specific cytotoxic T lymphocytes (CTLs) from peripheral-blood mononuclear cells (PBMCs) of 3 HLA-A*0201 donors. The decapeptide KDR288-297 was efficient in sensitizing target cells for recognition by a CTL clone at a concentration of 10 nM. More important, KDR288-297-specific CTLs lysed target cells transfected with HLA-A2/KDR cDNAs and a range of HLA-matched KDR+ angiogenic endothelial cells (aECs) and also recognized CD34+ endothelial progenitor cells. The specificity of CTLs was further confirmed by tetramer assay and cold-target inhibition assay. In addition, ex vivo exposure of aECs to the inflammatory cytokines enhanced CTL reactivity, which is in keeping with up-regulated KDR and HLA class 1 expression. In Matrigel assays, recognition of aECs by specific CTLs triggered an antivasular effect. These findings provide the first proof of the antigenic property of KDR protein and may be useful for devising new immunotherapeutic approaches to human cancers.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2000:240985 Document No. 132:292701 Novel methods for therapeutic vaccination. Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus

Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl. WO 2000020027 A2 20000413, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261 19981005; US 1998-PV105011 19981020.

AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

=> s (tahara h?/au or wada s?/au or tsunoda t?/au)
L8 12870 (TAHARA H?/AU OR WADA S?/AU OR TSUNODA T?/AU)

=> s 18 and KDR petpides
L9 0 L8 AND KDR PETPIDES

=> s 18 and KDR peptides
L10 0 L8 AND KDR PEPTIDES

=> s 18 adn KDR
MISSING OPERATOR L8 ADN
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s 18 and KDR
L11 2 L8 AND KDR

=> dup remove l11
PROCESSING COMPLETED FOR L11
L12 2 DUP REMOVE L11 (0 DUPLICATES REMOVED)

=> d l12 1-2 cbib abs

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2004:252541 Document No. 140:269532 KDR receptor-derived
HLA-A*2402- and HLA-A*0201-binding epitopes for angiogenesis inhibition and as vaccines against cancer, diabetic retinopathy, chronic rheumatoid arthritis, psoriasis and atherosclerosis. **Tahara, Hideaki; Wada, Satoshi; Tsunoda, Takuya** (Oncotherapy Science, Inc., Japan). PCT Int. Appl. WO 2004024766 A1 20040325, 100 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI,

CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2003-JP11722 20030912. PRIORITY: JP 2002-267285 20020912; JP 2003-62003 20030307; JP 2003-167042 20030611.

AB It is intended to provide a nonapeptide selected from among peptides comprising the amino acid sequences represented by SEQ ID NOS:2, 3, 5, 8, 11 and 12; a nonapeptide or a decapeptide selected from among peptides comprising the amino acid sequences represented by SEQ ID NOS:29, 30, 33, 34, 40 and 46; a peptide having an amino acid sequence derived from any of the above amino acid sequences by substitution or addition of one to several amino acids and being capable of inducing cytotoxic T cells; and drugs containing such a peptide for treating or preventing tumor. These KDR receptor-derived nona- and deca-peptides are HLA-A*2402-binding or HLA-A*0201-binding epitopes. These HLA-A*2402-binding and HLA-A*0201-binding epitope epitopes are useful for angiogenesis inhibition and as vaccines against cancer, diabetic retinopathy, chronic rheumatoid arthritis, psoriasis and atherosclerosis.

L12 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2003:441992 Document No.: PREV200300441992. Development of cancer immunotherapy against tumor angiogenesis. Wada, Satoshi [Reprint Author]; Tsunoda, Takuya [Reprint Author]; Baba, Toshiyuki [Reprint Author]; Tahara, Hideaki [Reprint Author]. Institute of Medical Science, University of Tokyo, Tokyo, Japan. Proceedings of the American Association for Cancer Research Annual Meeting, (July 2003) Vol. 44, pp. 167. print. Meeting Info.: 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA. July 11-14, 2003. ISSN: 0197-016X. Language: English.

=> d his

(FILE 'HOME' ENTERED AT 13:53:31 ON 02 AUG 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 13:53:47 ON 02 AUG 2007

L1 6610 S CTL EPITOPE
L2 1 S L1 AND KDR
L3 9651 S KDR
L4 0 S L3 AND NONOPEPTIDE
L5 637 S L3 AND PEPTIDE
L6 6 S L5 AND CTL
L7 2 DUP REMOVE L6 (4 DUPLICATES REMOVED)
L8 12870 S (TAHARA H?/AU OR WADA S?/AU OR TSUNODA T?/AU)
L9 0 S L8 AND KDR PETPIDES
L10 0 S L8 AND KDR PEPTIDES
L11 2 S L8 AND KDR
L12 2 DUP REMOVE L11 (0 DUPLICATES REMOVED)

=> s l3 and peptide?

L13 637 L3 AND PEPTIDE?

=> s l13 and pd<20020912.

2 FILES SEARCHED...

4 FILES SEARCHED...

L14 289 L13 AND PD<20020912

=> s k14 and T cell epitope

L15 0 K14 AND T CELL EPITOPE

=> s l13 and cytotoxic T cell

L16 2 L13 AND CYTOTOXIC T CELL

=> d l6 1-2 cbib abs

L6 ANSWER 1 OF 6 MEDLINE on STN

2006075035. PubMed ID: 16234362. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Sun Yuansheng; Stevanovic Stefan; Song Mingxia; Schwantes Astrid; Kirkpatrick C James; Schadendorf Dirk; Cichutek Klaus. (Division of Medical Biotechnology, Paul-Ehrlich-Institute, Paul-Ehrlich-Str 51-59, D-63225 Langen, Germany.. sunyu@pei.de) . Blood, (2006 Feb 15) Vol. 107, No. 4, pp. 1476-83. Electronic Publication: 2005-10-18. Journal code: 7603509. ISSN: 0006-4971. Pub. country: United States. Language: English.

AB Antigen-specific cancer immunotherapy directed toward tumor-nourishing angiogenic blood vessels holds the promise of high efficacy, low toxicity, and ease of application. To evaluate whether the human angiogenic kinase insert domain-containing receptor (KDR) can serve as a target for cellular immunotherapy, 19 **peptide** sequences with HLA-A*0201 motifs were selected by computer-based algorithms. Five **peptides** (KDR82-90, KDR288-297, KDR766-774, KDR1093-1101, KDR1035-1044) stimulated specific cytotoxic T lymphocytes (CTLs) from peripheral-blood mononuclear cells (PBMCs) of 3 HLA-A*0201 donors. The decapeptide KDR288-297 was efficient in sensitizing target cells for recognition by a CTL clone at a concentration of 10 nM. More important, KDR288-297-specific CTLs lysed target cells transfected with HLA-A2/KDR cDNAs and a range of HLA-matched KDR+ angiogenic endothelial cells (aECs) and also recognized CD34+ endothelial progenitor cells. The specificity of CTLs was further confirmed by tetramer assay and cold-target inhibition assay. In addition, ex vivo exposure of aECs to the inflammatory cytokines enhanced CTL reactivity, which is in keeping with up-regulated KDR and HLA class 1 expression. In Matrigel assays, recognition of aECs by specific CTLs triggered an antivasular effect. These findings provide the first proof of the antigenic property of KDR protein and may be useful for devising new immunotherapeutic approaches to human cancers.

L6 ANSWER 2 OF 6 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

2006082463 EMBASE The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Sun Y.; Stevanovic S.; Song M.; Schwantes A.; Kirkpatrick C.J.; Schadendorf D.; Cichutek K.. Y. Sun, Division of Medical Biotechnology, Paul-Ehrlich-Institute, Paul-Ehrlich-Str 51-59, D-63225 Langen, Germany. sunyu@pei.de. Blood Vol. 107, No. 4, pp. 1476-1483 15 Feb 2006.
Refs: 43.

ISSN: 0006-4971. E-ISSN: 0006-4971. CODEN: BLOOAW

Pub. Country: United States. Language: English. Summary Language: English. Entered STN: 20060316. Last Updated on STN: 20060316

AB Antigen-specific cancer immunotherapy directed toward tumor-nourishing angiogenic blood vessels holds the promise of high efficacy, low toxicity, and ease of application. To evaluate whether the human angiogenic kinase insert domain-containing receptor (KDR) can serve as a target for cellular immunotherapy, 19 **peptide** sequences with HLA-A*0201 motifs were selected by computer-based algorithms. Five **peptides** (KDR(82-90), KDR (288-297), KDR(766-774), KDR(1093-1101), KDR (1035-1044)) stimulated specific cytotoxic T lymphocytes (CTLs) from peripheral-blood mononuclear cells (PBMCs) of 3 HLA-A*0201 donors. The decapeptide KDR (288-297) was efficient in sensitizing target cells for recognition by a CTL clone at a concentration of 10 nM. More important, KDR (288-297)-specific CTLs lysed target cells transfected with HLA-A2/KDR cDNAs and a range of HLA-matched KDR(+) angiogenic endothelial cells (aECs) and also recognized CD34(+) endothelial progenitor cells. The specificity of CTLs was further confirmed by tetramer assay and cold-target inhibition assay. In addition, ex vivo exposure of aECs to the inflammatory cytokines

enhanced CTL reactivity, which is in keeping with up-regulated KDR and HLA class 1 expression. In Matrigel assays, recognition of aECs by specific CTLs triggered an antivascular effect. These findings provide the first proof of the antigenic property of KDR protein and may be useful for devising new immunotherapeutic approaches to human cancers. .COPYRG. 2006 by The American Society of Hematology.

=> s l14 and CTL
L17 1 L14 AND CTL

=> d l17 cbib abs

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2000:240985 Document No. 132:292701 Novel methods for therapeutic vaccination. Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl. WO 2000020027 A2 20000413, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DE, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261 19981005; US 1998-PV105011 19981020.

AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	78.90	79.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

STN INTERNATIONAL LOGOFF AT 13:59:43 ON 02 AUG 2007